🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Christina Curtis, PhD, MSc (Christina Curtis) with our DFCI BOC research fellows following the DF/HCC Breast & Gynecologic Cancer Symposium. Thank you for your time and great discussion, Dr. Curtis!

Eloquent discussion of early relapse TNBC by Sara Tolaney following the IMPASSION132 results #ESMOBreast24. The COMPASS trial led by Barbara Pistilli Gustave Roussy targeting this difficult disease with innovative strategies is eagerly awaited Thomas Grinda JoanaMRibeiro2 OncoAlert

Results of IMpassion132 study are negative. Early relapsed TNBC remain an unmet clinical need. Special thanks to Sara Tolaney for presenting our COMPASS-TNBC platform trial study, which is exploring innovative therapies for these patients. Gustave Roussy Barbara Pistilli

Another #ESMObreast24...Another science productive and awarded year for BreastUnit_DMO Gustave Roussy Gustave Roussy Cancer Survivorship Group team! Barbara Pistilli Suzette delaloge Elie Rassy @JZeghondi @fedgiugliano Thomas Grinda Ines Vaz Luis Julia Dixon-Douglas Fernanda Mosele Antonio Di Meglio, MD, PhD Martina Pagliuca

Key findings from analysis of outcomes to 1L anti-HER2 therapy in those with HER2+ MBC within ESME cohort -25% progression free at 3y -Of pts progression-free at 3y, 68% will remain progression-free at 5y -biomarkers needed to identify these pts upfront

Important SOFT/TEXT subanalysis presented at #ESMOBreast24 by Otto Metzger showing a greater magnitude of AI vs Tamoxifen benefit in premenopausal patients with lobular histology OncoAlert #bcsm

Updated data for Pfizer cdk4-selective inhibitor PF-07220060 -pt population: 100% prior cdk4/6i -favorable tox profile -32% ORR, median PFS 8.1 mo -efficacy regardless of ESR1 and PIK3CA mutation status

Dr. Nancy Lin (Nancy Lin, MD) discussed advances in medical treatment in today's #ESMObreast24 educational session on the management of #BrainMetastases from early detection to local and systemic treatments. #BreastCancerBrainMetastasis #BCBM #LMD cattendee.abstractsonline.com/meeting/20743/…

Being an oncologist is the best job in the world. Honored to share this discussion with one of my patients. medscape.com/viewarticle/99…

Less than a week to what promises to be a terrific ASCO24. Multiple trials with practice changing potential, including with ADCs challenging our HER2 categories, CDK4/6 inhibitors beyond progression, adjuvant IO for TNBC and much more. See you in Chicago next week! #bcsm #ASCO24

As we approach June, Brain & Spine metastasis awareness month and ASCO 2024 conference, here are a list of Breast Cancer related Brain Metastasis abstracts that I am looking forward to learning more about! #metsgetsawareness brainspinemetastasis.org Duke Center for Brain and Spine Metastasis Duke Cancer

✨Cette année à l'#ASCO24, les médecins-chercheurs de Gustave Roussy ont participé à plus de 130 abstracts retenus par le comité scientifique du congrès, témoignant de la qualité de la recherche menée à l’Institut, et de son impact à l’échelle mondiale. #DreamTeam 🥇

As I try to figure out INAVO120, I would like to point out that patients with PIK3CA mutations do very well on first line Abema/Fulv or Ribo/Fulv with median PFS beyond 16 months in registrational trials. Palbo/Fulv as a control arm is questionable Thanks LARVOL for dataset.

Interested in how Digital Health is transforming oncology care delivery? Dont miss the Oral Care Delivery Session. We are thrilled to present our work evaluating the impact of Social Determinants of Health on RPM #DigitalHealth #EquitableCare #ASCO2024 June 4th 11:45 S100bc

TBCRC 049: Tucatinib, trastuzumab, capecitabine for HER2+ LMD -The first prospective LMD trial to show all of the following: -therapeutic drug levels in CSF -intracranial response -improvement in symptoms and QoL -extended OS compared to historical controls

Much talk of BICR (blinded independent central review) ASCO. cf ascopubs.org/doi/10.1200/JC… "BICRs may introduce bias because of informative censoring, which results from having to censor unconfirmed locally determined progressions." i.e. tends to overstate PFS HT Ruth O'Regan

Insightful perspective on outcomes that should influence ou treatment choices for patients with brain metastases from Nancy Lin, MD Dana-Farber’s Breast Oncology Center @Asco2024

Five trials of AC/T chemo +/- carboplatin for stage 2/3 TNBC with DFS/EFS endpoints. CALGB 40603 (❎) BrighTNess (✅) GeparSixto (✅) Gupta S, (SABCS) 2022, GS5-01 (✅) BR 15-1 PEARLY ASCO 2024 (✅) Unofficial meta-analyis: looks like carboplatin reduces recurrence in TNBC.

📢 Les spécialistes du #cancer du sein de Gustave Roussy, rassemblés pour la traditionnelle photo à l’ASCO. Fiers de nos équipes ! 💪 #ASCO24

Is HER3 a new major player in Breast Cancer Treatment? Francesca Papa, an outstanding Research Fellow at Gustave Roussy 's Breast Cancer Group, provides a fantastic review. authors.elsevier.com/sd/article/S03… #ICARUSBREAST01 #PatritumabDeruxtecan Barbara Pistilli Elie Rassy JoanaMRibeiro2